Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{184110,
        author = {Nandini Rompicharla and Pavithra Gadde and Prasanna Thumpati and Veeranki Meghana and Siva Gowri Tanuja Ramanadham and Dr. Garlapati Usha Kiran},
        title = {EMERGING ROLE OF LENACAPAVIR IN HIV THERAPY: A REVIEW OF ITS PHARMACOLOGY, EFFICACY},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {4},
        pages = {40-44},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=184110},
        abstract = {Human immunodeficiency virus (HIV) is a type of retrovirus that spreads through blood, sexual contact, childbirth, or breastfeeding. It specifically targets CD4+ T lymphocytes, which are crucial for a healthy immune system. Among the strains, HIV-1 is the most prevalent and aggressive, while HIV-2 progresses more slowly and is primarily found in West Africa. The life cycle of HIV includes several key steps: gp120 binds to CD4 receptors, gp41 facilitates fusion, reverse transcription occurs, the virus integrates into the host's genome, and finally, infectious virions are produced. Lenacapavir is a groundbreaking HIV-1 capsid inhibitor that takes a fresh approach to tackle resistant infections. It attaches to the capsid protein subunits, effectively blocking early processes like nuclear import and reverse transcription, as well as later stages such as assembly and maturation, which results in the production of defective viruses. This drug is particularly effective against multidrug-resistant strains and shows minimal cross-resistance. With its extended pharmacokinetics, Lenacapavir allows for subcutaneous dosing every six months after an initial oral loading dose, which helps improve patient adherence. Clinical trials have shown significant reductions in viral load, making it a promising option for those dealing with resistant and hard-to-treat HIV cases.},
        keywords = {Capsid inhibitor, Lenacapavir, Antiretroviral therapy, Multidrug-resistant HIV, Nuclear import inhibition, Long-acting therapy, Patient adherence.},
        month = {August},
        }